Format
Sort by

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 100

1.

Retrospective study of pemetrexed as salvage therapy for central nervous system lymphoma.

Zhang JP, Lee EQ, Nayak L, Doherty L, Kesari S, Muzikansky A, Norden AD, Chen H, Wen PY, Drappatz J.

J Neurooncol. 2013 Oct;115(1):71-7. doi: 10.1007/s11060-013-1196-1. Epub 2013 Jul 5.

PMID:
23828279
2.

Pemetrexed in the treatment of relapsed/refractory primary central nervous system lymphoma.

Raizer JJ, Rademaker A, Evens AM, Rice L, Schwartz M, Chandler JP, Getch CC, Tellez C, Grimm SA.

Cancer. 2012 Aug 1;118(15):3743-8. doi: 10.1002/cncr.26709. Epub 2011 Dec 16.

3.

Salvage therapy with bendamustine for methotrexate refractory recurrent primary CNS lymphoma: a retrospective case series.

Chamberlain MC.

J Neurooncol. 2014 May;118(1):155-62. doi: 10.1007/s11060-014-1411-8. Epub 2014 Mar 1.

PMID:
24584709
4.

[Curative effect of pemetrexed on the treatment of relapsed primary central nervous system lymphoma].

Wang Y, Wang X, Zhao Y, Tao R, Zhu Y, Zhao R, Xu J.

Zhonghua Xue Ye Xue Za Zhi. 2014 Jan;35(1):46-9. doi: 10.3760/cma.j.issn.0253-2727.2014.01.012. Chinese.

PMID:
24602732
5.

Platine and cytarabine-based salvage treatment for primary central nervous system lymphoma.

del Rio MS, Choquet S, Hoang-Xuan K, Glaisner S, Fourme E, Janvier M, Soussain C.

J Neurooncol. 2011 Nov;105(2):409-14. doi: 10.1007/s11060-011-0608-3. Epub 2011 Jun 9.

PMID:
21656329
6.

Isolated central nervous system relapse of systemic lymphoma (SCNSL): clinical features and outcome of a retrospective analysis.

Patrij K, Reiser M, Wätzel L, Pels H, Kowoll A, Herrlinger U, Engert A, Linnebank M, Schackert G, Vogt-Schaden M, Egerer G, Lamprecht M, Batchelor TT, Schlegel U, Schmidt-Wolf IG; International Primary CNS Lymphoma Collaborative Group (IPCG).

Ger Med Sci. 2011;9:Doc11. doi: 10.3205/000134. Epub 2011 May 2.

7.

Open-label, single-arm phase II study of pemetrexed in the treatment of patients with recurrent or metastatic nasopharyngeal carcinoma who have had prior platinum-based chemotherapy.

Zhang Y, Zhao L, Huang P, Wu J, Wang F, Huang Y, Zhang L.

Cancer Chemother Pharmacol. 2012 Oct;70(4):611-5. Epub 2012 Aug 19.

PMID:
22903536
8.

Late relapse in primary central nervous system lymphoma: clonal persistence.

Nayak L, Hedvat C, Rosenblum MK, Abrey LE, DeAngelis LM.

Neuro Oncol. 2011 May;13(5):525-9. doi: 10.1093/neuonc/nor014. Epub 2011 Mar 3.

9.

Results of a phase II study of pemetrexed as first-line chemotherapy in patients with advanced or metastatic breast cancer.

Robert NJ, Conkling PR, O'Rourke MA, Kuefler PR, McIntyre KJ, Zhan F, Asmar L, Wang Y, Shonukan OO, O'Shaughnessy JA.

Breast Cancer Res Treat. 2011 Feb;126(1):101-8. doi: 10.1007/s10549-010-1286-0. Epub 2010 Dec 25.

PMID:
21188632
10.

[Efficacy of salvage chemotherapy in the advanced non-small cell lung cancer patients who failed the treatment of chemotherapy and EGFR-TKI].

Fan Y, Huang ZY, Yu HF, Luo LH.

Zhonghua Zhong Liu Za Zhi. 2010 Nov;32(11):859-63. Chinese.

PMID:
21223694
11.

Pharmacokinetics and efficacy of pemetrexed in patients with brain or leptomeningeal metastases.

Kumthekar P, Grimm SA, Avram MJ, Kaklamani V, Helenowski I, Rademaker A, Cianfrocca M, Gradishar W, Patel J, Mulcahy M, McCarthy K, Raizer JJ.

J Neurooncol. 2013 Apr;112(2):247-55. doi: 10.1007/s11060-013-1055-0. Epub 2013 Jan 25.

PMID:
23354655
12.

Results of intensive chemotherapy followed by hematopoietic stem-cell rescue in 22 patients with refractory or recurrent primary CNS lymphoma or intraocular lymphoma.

Soussain C, Suzan F, Hoang-Xuan K, Cassoux N, Levy V, Azar N, Belanger C, Achour E, Ribrag V, Gerber S, Delattre JY, Leblond V.

J Clin Oncol. 2001 Feb 1;19(3):742-9.

PMID:
11157026
13.

Salvage treatment with etoposide (VP-16), ifosfamide and cytarabine (Ara-C) for patients with recurrent primary central nervous system lymphoma.

Arellano-Rodrigo E, López-Guillermo A, Bessell EM, Nomdedeu B, Montserrat E, Graus F.

Eur J Haematol. 2003 Apr;70(4):219-24.

PMID:
12656744
14.

Relapse of primary central nervous system lymphoma: clinical features, outcome and prognostic factors.

Jahnke K, Thiel E, Martus P, Herrlinger U, Weller M, Fischer L, Korfel A; German Primary Central Nervous System Lymphoma Study Group.

J Neurooncol. 2006 Nov;80(2):159-65. Epub 2006 May 13.

PMID:
16699873
15.

Results of combined-modality therapy for primary and secondary malignant lymphoma of the central nervous system (CNS).

Kawamura T, Koga S, Okamoto M, Kanno T, Iwamura H.

Radiat Med. 2001 May-Jun;19(3):145-9.

PMID:
11467381
16.

Methotrexate re-challenge for recurrent primary central nervous system lymphoma.

Pentsova E, Deangelis LM, Omuro A.

J Neurooncol. 2014 Mar;117(1):161-5. doi: 10.1007/s11060-014-1370-0. Epub 2014 Jan 31.

PMID:
24481997
17.

Treatment of relapsed central nervous system lymphoma with high-dose methotrexate.

Plotkin SR, Betensky RA, Hochberg FH, Grossman SA, Lesser GJ, Nabors LB, Chon B, Batchelor TT.

Clin Cancer Res. 2004 Sep 1;10(17):5643-6.

18.

O⁶-methylguanine-DNA methyltransferase promoter methylation in 45 primary central nervous system lymphomas: quantitative assessment of methylation and response to temozolomide treatment.

Adachi J, Mishima K, Wakiya K, Suzuki T, Fukuoka K, Yanagisawa T, Matsutani M, Sasaki A, Nishikawa R.

J Neurooncol. 2012 Mar;107(1):147-53. doi: 10.1007/s11060-011-0721-3. Epub 2011 Oct 4.

PMID:
21968944
19.

Long-term remission of primary central nervous system lymphoma by intensified methotrexate chemotherapy.

Watanabe T, Katayama Y, Yoshino A, Komine C, Yokoyama T, Fukushima T.

J Neurooncol. 2003 May;63(1):87-95.

PMID:
12814260
20.

Efficacy and toxicity of pemetrexed as a third-line treatment for non-small cell lung cancer.

Sun JM, Lee KW, Kim JH, Kim YJ, Yoon HI, Lee JH, Lee CT, Lee JS.

Jpn J Clin Oncol. 2009 Jan;39(1):27-32. doi: 10.1093/jjco/hyn118. Epub 2008 Oct 24.

Items per page

Supplemental Content

Write to the Help Desk